Literature DB >> 18167468

Evaluation of bone and mineral disorders.

Laleh Ardeshirpour1, David E C Cole, Thomas O Carpenter.   

Abstract

Children and adolescents may be affected by a host of metabolic diseases that primarily impact the integrity of the skeletal system. Often, the underlying problem involves impairment in calcium, phosphate or vitamin D homeostasis. Alternatively, hormonal imbalances, such as in parathyroid hormone, may be at the heart of the problem. Recent advances in our diagnostic capabilities, such as the wide availability of assays for parathyroid hormone, ionized calcium, and vitamin D metabolites; genetic testing for hereditary disorders of bone; and widespread use of bone densitometry technologies, have improved our diagnostic acumen. However, at the same time, familiarity with these new developments is limited and may lead to misinterpretation without a careful understanding of certain features of these tests. Thus, our mission is to discuss the strengths and shortcomings of these diagnostic modalities and to provide a concise review of nuances involved in interpretation of data when using these techniques.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18167468

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  15 in total

1.  Evaluation of hypophosphatemia: lessons from patients with genetic disorders.

Authors:  Justine Bacchetta; Isidro B Salusky
Journal:  Am J Kidney Dis       Date:  2011-11-09       Impact factor: 8.860

2.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

3.  Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children.

Authors:  Luisa F Gonzalez Ballesteros; Nina S Ma; Rebecca J Gordon; Leanne Ward; Philippe Backeljauw; Halley Wasserman; David R Weber; Linda A DiMeglio; Julie Gagne; Robert Stein; Declan Cody; Kimber Simmons; Paul Zimakas; Lisa Swartz Topor; Sungeeta Agrawal; Andrew Calabria; Peter Tebben; Ruth Faircloth; Erik A Imel; Linda Casey; Thomas O Carpenter
Journal:  Bone       Date:  2017-02-04       Impact factor: 4.398

4.  Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Authors:  Thomas O Carpenter; Karl L Insogna; Jane H Zhang; Bruce Ellis; Sherril Nieman; Christine Simpson; Elizabeth Olear; Caren M Gundberg
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

5.  Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment.

Authors:  Aurélia Bertholet-Thomas; Debora Claramunt-Taberner; Ségolène Gaillard; Georges Deschênes; Elisabeth Sornay-Rendu; Pawel Szulc; Martine Cohen-Solal; Solenne Pelletier; Marie-Christine Carlier; Pierre Cochat; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2018-02-12       Impact factor: 3.714

Review 6.  Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.

Authors:  Justine Bacchetta; Julie Bernardor; Charlotte Garnier; Corentin Naud; Bruno Ranchin
Journal:  Calcif Tissue Int       Date:  2020-01-29       Impact factor: 4.333

7.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy.

Authors:  N Nasomyont; L N Hornung; H Wasserman
Journal:  Osteoporos Int       Date:  2019-12-02       Impact factor: 4.507

8.  Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.

Authors:  Mark R Hanudel; Katherine Wesseling-Perry; Barbara Gales; Georgina Ramos; Vicky Campbell; Kristen Ethridge; Mary Scotti; David A Elashoff; Juan Alejos; Brian Reemtsen; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2015-11-02       Impact factor: 3.714

9.  Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients.

Authors:  Blair Limm-Chan; Katherine Wesseling-Perry; Meghan H Pearl; Grace Jung; Eileen Tsai-Chambers; Patricia L Weng; Mark R Hanudel
Journal:  Pediatr Nephrol       Date:  2021-04-26       Impact factor: 3.714

10.  Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.

Authors:  Mark R Hanudel; Marciana Laster; Georgina Ramos; Barbara Gales; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2018-06-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.